BVXV - Biondvax Pharmaceuticals Ltd - ADR
Close
1.305
-0.045 -3.448%
Share volume: 3,499
Last Updated: Fri 01 Sep 2023 10:00:00 PM CEST
Biological Product (except Diagnostic) Manufacturing :
-3.41%
PREVIOUS CLOSE
CHG
CHG%
$1.35
-0.05
-3.33%
Fundamental analysis
58%
Profitability
50%
Dept financing
50%
Liquidity
45%
Performance
70%
Performance
5 Days
-1.09%
1 Month
-2.61%
3 Months
-23.24%
6 Months
-43.35%
1 Year
24.29%
2 Year
-46.95%
Key data
Stock price
$1.30
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.53 - $11.49
52 WEEK CHANGE
$0.24
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Ron Babecoff
Region: US
Website: http://www.biondvax.com
Employees: 0
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing
Region: US
Website: http://www.biondvax.com
Employees: 0
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing
biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. biondvax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
Recent news